[Articles] Chromatin organisation and cancer prognosis: a pan-cancer study

The consistent prognostic prediction of Nucleotyping in different biological and technical circumstances suggests that the marker of chromatin heterogeneity can be reliably assessed in routine clinical practice and could be used to objectively assist decision making in a range of clinical settings. An immediate application would be to identify high-risk patients with stage II colorectal cancer who might have greater absolute benefit from adjuvant chemotherapy. Clinical trials are warranted to evaluate the survival benefit and cost-effectiveness of using Nucleotyping to guide treatment decisions in multiple clinical settings.

Source: The Lancet Oncology - February 2, 2018 Category: Cancer & Oncology Authors: Andreas Kleppe, Fritz Albregtsen, Ljiljana Vlatkovic, Manohar Pradhan, Birgitte Nielsen, Tarjei S Hveem, Hanne A Askautrud, Gunnar B Kristensen, Arild Nesbakken, Jone Trovik, H åkon Wæhre, Ian Tomlinson, Neil A Shepherd, Marco Novelli, David J Kerr, Hå Tags: Articles Source Type: research